Kairos Pharma, Ltd. (KAPA)
$0.81-15.62%Close
SELLCRISIS · day 41
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $17M
- Beta
- 1.45
- P/E (TTM)
- -0.59
- Short % float
- 1.26%
- Days to cover
- 1.0
- SI change
- -1.1%
- 1W
- -48.08%
- 1M
- -51.79%
- vs SPY 1W
- -49.24%
- vs SPY 1M
- -54.78%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on KAPA?
- LOPJLB’s latest quantitative signal on Kairos Pharma, Ltd. (KAPA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is KAPA in?
- Kairos Pharma, Ltd. (KAPA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Kairos Pharma, Ltd. (KAPA) do?
- Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, I…